Vetr upgraded shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a buy rating in a report released on Wednesday morning. They currently have $6.64 price objective on the biotechnology company’s stock.
Other research analysts also recently issued reports about the company. HC Wainwright dropped their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a buy rating on the stock in a research report on Thursday, May 18th. Zacks Investment Research raised Aurinia Pharmaceuticals from a hold rating to a buy rating and set a $7.00 price objective on the stock in a report on Tuesday, August 15th. Cantor Fitzgerald set a $14.00 price objective on Aurinia Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 11th. Finally, BidaskClub lowered Aurinia Pharmaceuticals from a hold rating to a sell rating in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $9.71.
Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.27 on Wednesday. The company has a 50 day moving average of $6.22 and a 200 day moving average of $6.66. Aurinia Pharmaceuticals has a 52-week low of $2.02 and a 52-week high of $10.54. The stock’s market capitalization is $523.45 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. Analysts predict that Aurinia Pharmaceuticals will post ($0.94) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/17/vetr-inc-upgrades-aurinia-pharmaceuticals-inc-auph-to-buy.html.
Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in Aurinia Pharmaceuticals by 8.6% in the 2nd quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 1,341 shares in the last quarter. Jane Street Group LLC acquired a new stake in Aurinia Pharmaceuticals in the 1st quarter valued at $155,000. Cutler Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at $184,000. Investment Centers of America Inc. acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at $184,000. Finally, Two Sigma Securities LLC acquired a new stake in Aurinia Pharmaceuticals in the 1st quarter valued at $240,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.